

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of the claims:

Claims 1-53 (canceled).

54 (new). A method for suppressing undesired tissue formation or for restoring the original appearance of tissue at a site of tissue damage in the upper respiratory tract or ear of a patient comprising, administering to a patient in need thereof at the site of tissue damage, an amount of liposomes sufficient to suppress undesired tissue formation or to restore the original appearance of the tissue, said liposomes containing povidone iodine.

55 (new). The method of claim 54, wherein the liposomes further contain an anti-inflammatory agent.

56 (new). The method of claim 54, wherein the liposomes further contain another agent that promotes granulation or epithelialization.

57 (new). The method of claim 54, wherein the liposomes further contain an anesthetic.

58 (new). The method of claim 54, wherein the liposomes further contain a conserving agent or an antioxidant.

59 (new). The method of claim 56, wherein the agent is dexpanthenol, allatonin, azulene, tannin, or a vitamin B compound.

60 (new). The method of claim 54, wherein the liposomes have a diameter in the range from about 1 nm to about 20,000 nm.

61 (new). The method of claim 54, wherein the liposomes have a diameter in the range from about 50 nm to about 4,000 nm.

62 (new). The method of claim 54, wherein the liposomes have a diameter in the range from about 500 nm to about 2,500 nm.

63 (new). The method of claim 54, wherein the liposomes have a diameter of about 1,000 nm.

64 (new). The method of claim 54, wherein the liposomes comprise a liposome membrane forming substance that is present in an amount between about 1% to about 10%, by weight, of the liposomes.

65 (new). The method of claim 64, wherein the liposomes comprise a liposome membrane forming substance that is present in an amount between about 1% to about 5%, by weight, of the liposomes.

66 (new). The method of claim 65, wherein the liposomes comprise a liposome membrane forming substance that is present in an amount of about 4%, by weight, of the liposomes.

67 (new). The method of claim 54, wherein the liposomes are lecithin liposomes.

68 (new). The method of claim 67, wherein the lecithin liposomes are hydrogenated soy bean lecithin liposomes.

69 (new). The method of claim 54, wherein the liposomes contain about 0.1% to about 10% by weight povidone iodine.

70 (new). The method of claim 54, wherein the liposomes contain about 3% by weight povidone iodine.

71 (new). The method of claim 54, wherein the liposomes contain about 4.5% by weight povidone iodine.

72 (new). The method of claim 54, wherein the liposomes further contain an antibiotic.

73 (new). The method of claim 54, wherein the liposomes further contain a corticosteroid.

74 (new). The method of claim 54, wherein the patient is a human patient.

75 (new). The method of claim 54, wherein the site of tissue damage is in the larynx.

76 (new). The method of claim 54, wherein the site of tissue damage is in the middle ear.

77 (new). A method for suppressing scar formation at a site of tissue damage in the upper respiratory tract or ear of a patient comprising, administering to a patient in need thereof at the site of tissue damage, an amount of liposomes sufficient to suppress scar formation, said liposomes containing povidone iodine.

78 (new). A method for suppressing undesired tissue formation or for restoring the original appearance of tissue at a site of tissue damage in the ciliary epithelial tissues in the upper respiratory tract or ear of a patient comprising, administering to a patient in need thereof at the site of tissue damage, an amount of liposomes sufficient to suppress undesired tissue formation or to restore the original appearance of the tissue, said liposomes containing povidone iodine.